دورية أكاديمية
Osteoprotegerin and rank ligand expression in prostate cancer.
| العنوان: | Osteoprotegerin and rank ligand expression in prostate cancer. |
|---|---|
| المؤلفون: | Brown JM; Department of Urology, University of Washington, Seattle, Washington, USA., Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL |
| المصدر: | Urology [Urology] 2001 Apr; Vol. 57 (4), pp. 611-6. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 0366151 Publication Model: Print Cited Medium: Internet ISSN: 1527-9995 (Electronic) Linking ISSN: 00904295 NLM ISO Abbreviation: Urology Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York : Elsevier Science Original Publication: Ridgewood, N.J., Professional Medical Services Co. |
| مواضيع طبية MeSH: | Bone Neoplasms/*chemistry , Bone Neoplasms/*secondary , Carrier Proteins/*analysis , Glycoproteins/*analysis , Membrane Glycoproteins/*analysis , Prostatic Neoplasms/*chemistry , Receptors, Cytoplasmic and Nuclear/*analysis, Aged ; Aged, 80 and over ; Base Sequence ; Cytokines/analysis ; Glycoproteins/genetics ; Humans ; Immunohistochemistry ; Lymphatic Metastasis/pathology ; Male ; Middle Aged ; Osteoprotegerin ; Prostate/chemistry ; RANK Ligand ; RNA, Messenger/analysis ; Receptor Activator of Nuclear Factor-kappa B ; Receptors, Cytoplasmic and Nuclear/genetics ; Receptors, Tumor Necrosis Factor |
| مستخلص: | Objectives: To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling. Methods: Tissues from 28 patients with CaP and from 4 normal organ donors were analyzed by reverse transcriptase-polymerase chain reaction and immunohistochemistry for the expression of OPG and RANKL. Results: OPG and RANKL messages were detected in both normal and cancerous prostate samples. In the normal prostate, OPG protein was detected in luminal epithelial and stromal cells (5% to 65% and 15% to 70%, respectively) and RANKL immunoreactivity was observed in 15% to 50% of basal epithelial cells, 40% to 90% of luminal epithelial cells, and 70% to 100% of stromal cells. OPG was not detected in 8 of 10 primary CaP specimens; RANKL was heterogeneously expressed in 10 of 11 CaP specimens. The percentage of tumor cells expressing OPG and RANKL was significantly increased in all CaP bone metastases compared with nonosseous metastases or primary CaP. Conclusions: CaP bone metastases were consistently immunoreactive for both OPG and RANKL compared with nonosseous metastases or primary CaP. The presence of these crucial bone resorption regulators in CaP bone metastases suggests a mechanism whereby CaP cells may modulate bone turnover and has profound implications for the establishment and development of CaP bone metastases in advanced disease. |
| معلومات مُعتمدة: | DK 47656-07 United States DK NIDDK NIH HHS |
| المشرفين على المادة: | 0 (Carrier Proteins) 0 (Cytokines) 0 (Glycoproteins) 0 (Membrane Glycoproteins) 0 (Osteoprotegerin) 0 (RANK Ligand) 0 (RNA, Messenger) 0 (Receptor Activator of Nuclear Factor-kappa B) 0 (Receptors, Cytoplasmic and Nuclear) 0 (Receptors, Tumor Necrosis Factor) 0 (TNFRSF11A protein, human) 0 (TNFRSF11B protein, human) 0 (TNFSF11 protein, human) |
| تواريخ الأحداث: | Date Created: 20010418 Date Completed: 20010521 Latest Revision: 20190714 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/s0090-4295(00)01122-5 |
| PMID: | 11306358 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1527-9995 |
|---|---|
| DOI: | 10.1016/s0090-4295(00)01122-5 |